Dislipidemiaren aurkako tratamentu berriak nanopartikulak erabiliz

Abstract

Hiperkolesterolemia dislipidemia ohikoena da, eta odoleko LDL-C (ingelesetik, low-densitylipoprotein cholesterol) maila altua izateagatik bereizgarria da. LDL-C maila altuak zuzenean lotu izandira gaixotasun kardiobaskularrak garatzeko arriskuarekin; horregatik, garrantzitsua da gaixotasunhorri aurre egiteko terapia berriak garatzea. Ikerketa honen helburua izan da ApoE (ingelesetik,Apolipoprotein E) proteinan oinarritutako nanopartikulak garatzea azido bempedoikoaren, estatineneta siRNA (ingelesetik, small interfering RNA)-ren bidezko tratamenduen eraginkortasuna hobetzeko.Izan ere, LDL barneraketa eta LDLr (ingelesetik, low-density lipoprotein receptor) adierazpenakuantifikatu dira tratamenduak probatu ostean, eta emaitza esangarriak lortu dira.Hypercholesterolemia is the most frequent dyslipidemia and is characterized by its high levelof Low-density Lipoprotein cholesterol (LDL-C) in blood. High LDL-C levels are directly related tothe risk of developing cardiovascular diseases, so it is important to develop new therapies to treat thisdisease. The objective of this study was to develop ApoE protein based nanoparticles to improve theefficacy of treatments with bempedoic acid, statins and small interfering RNA (siRNA). In fact, theuptake of LDL and low-density lipoprotein receptor (LDLr) expression have been quantified aftertreatment testing and significant results have been obtained.